nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyl aminolevulinate—Pain of skin—Bleomycin—lymphatic system cancer	0.0672	0.0672	CcSEcCtD
Methyl aminolevulinate—Localized exfoliation—Bleomycin—lymphatic system cancer	0.0588	0.0588	CcSEcCtD
Methyl aminolevulinate—Skin hyperpigmentation—Mechlorethamine—lymphatic system cancer	0.0561	0.0561	CcSEcCtD
Methyl aminolevulinate—Blister—Mechlorethamine—lymphatic system cancer	0.0463	0.0463	CcSEcCtD
Methyl aminolevulinate—Skin ulcer—Mechlorethamine—lymphatic system cancer	0.0428	0.0428	CcSEcCtD
Methyl aminolevulinate—Skin infection—Mitoxantrone—lymphatic system cancer	0.0426	0.0426	CcSEcCtD
Methyl aminolevulinate—Skin hyperpigmentation—Bleomycin—lymphatic system cancer	0.0266	0.0266	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Mechlorethamine—lymphatic system cancer	0.0253	0.0253	CcSEcCtD
Methyl aminolevulinate—Skin hyperpigmentation—Carmustine—lymphatic system cancer	0.0233	0.0233	CcSEcCtD
Methyl aminolevulinate—Burning sensation—Carmustine—lymphatic system cancer	0.0199	0.0199	CcSEcCtD
Methyl aminolevulinate—Ulcer—Bleomycin—lymphatic system cancer	0.0168	0.0168	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Bleomycin—lymphatic system cancer	0.0151	0.0151	CcSEcCtD
Methyl aminolevulinate—Ulcer—Mitoxantrone—lymphatic system cancer	0.0136	0.0136	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Carmustine—lymphatic system cancer	0.0132	0.0132	CcSEcCtD
Methyl aminolevulinate—Infection—Mechlorethamine—lymphatic system cancer	0.0118	0.0118	CcSEcCtD
Methyl aminolevulinate—Swelling—Carmustine—lymphatic system cancer	0.0114	0.0114	CcSEcCtD
Methyl aminolevulinate—Eye pain—Carmustine—lymphatic system cancer	0.0111	0.0111	CcSEcCtD
Methyl aminolevulinate—Skin hyperpigmentation—Methotrexate—lymphatic system cancer	0.0108	0.0108	CcSEcCtD
Methyl aminolevulinate—Swelling—Mitoxantrone—lymphatic system cancer	0.0106	0.0106	CcSEcCtD
Methyl aminolevulinate—Face oedema—Carmustine—lymphatic system cancer	0.00969	0.00969	CcSEcCtD
Methyl aminolevulinate—Burning sensation—Methotrexate—lymphatic system cancer	0.00922	0.00922	CcSEcCtD
Methyl aminolevulinate—Oedema—Teniposide—lymphatic system cancer	0.00877	0.00877	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00877	0.00877	CcSEcCtD
Methyl aminolevulinate—Infection—Teniposide—lymphatic system cancer	0.00872	0.00872	CcSEcCtD
Methyl aminolevulinate—Pruritus—Mechlorethamine—lymphatic system cancer	0.00842	0.00842	CcSEcCtD
Methyl aminolevulinate—Skin ulcer—Methotrexate—lymphatic system cancer	0.00823	0.00823	CcSEcCtD
Methyl aminolevulinate—Discomfort—Fludarabine—lymphatic system cancer	0.00795	0.00795	CcSEcCtD
Methyl aminolevulinate—Oedema—Fludarabine—lymphatic system cancer	0.00771	0.00771	CcSEcCtD
Methyl aminolevulinate—Infection—Fludarabine—lymphatic system cancer	0.00766	0.00766	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00756	0.00756	CcSEcCtD
Methyl aminolevulinate—Rash—Mechlorethamine—lymphatic system cancer	0.0075	0.0075	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Mechlorethamine—lymphatic system cancer	0.0075	0.0075	CcSEcCtD
Methyl aminolevulinate—Nausea—Mechlorethamine—lymphatic system cancer	0.00707	0.00707	CcSEcCtD
Methyl aminolevulinate—Urticaria—Teniposide—lymphatic system cancer	0.00697	0.00697	CcSEcCtD
Methyl aminolevulinate—Erythema—Bleomycin—lymphatic system cancer	0.00693	0.00693	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Fludarabine—lymphatic system cancer	0.00692	0.00692	CcSEcCtD
Methyl aminolevulinate—Ulcer—Methotrexate—lymphatic system cancer	0.00677	0.00677	CcSEcCtD
Methyl aminolevulinate—Fatigue—Fludarabine—lymphatic system cancer	0.00665	0.00665	CcSEcCtD
Methyl aminolevulinate—Pain—Fludarabine—lymphatic system cancer	0.00659	0.00659	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Carmustine—lymphatic system cancer	0.00649	0.00649	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Teniposide—lymphatic system cancer	0.00646	0.00646	CcSEcCtD
Methyl aminolevulinate—Asthenia—Teniposide—lymphatic system cancer	0.00629	0.00629	CcSEcCtD
Methyl aminolevulinate—Pruritus—Teniposide—lymphatic system cancer	0.00621	0.00621	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Methotrexate—lymphatic system cancer	0.00612	0.00612	CcSEcCtD
Methyl aminolevulinate—Erythema—Carmustine—lymphatic system cancer	0.00605	0.00605	CcSEcCtD
Methyl aminolevulinate—Discomfort—Bleomycin—lymphatic system cancer	0.00583	0.00583	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00568	0.00568	CcSEcCtD
Methyl aminolevulinate—Oedema—Bleomycin—lymphatic system cancer	0.00565	0.00565	CcSEcCtD
Methyl aminolevulinate—Erythema—Mitoxantrone—lymphatic system cancer	0.00562	0.00562	CcSEcCtD
Methyl aminolevulinate—Infection—Bleomycin—lymphatic system cancer	0.00562	0.00562	CcSEcCtD
Methyl aminolevulinate—Asthenia—Fludarabine—lymphatic system cancer	0.00553	0.00553	CcSEcCtD
Methyl aminolevulinate—Rash—Teniposide—lymphatic system cancer	0.00553	0.00553	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Teniposide—lymphatic system cancer	0.00553	0.00553	CcSEcCtD
Methyl aminolevulinate—Headache—Teniposide—lymphatic system cancer	0.0055	0.0055	CcSEcCtD
Methyl aminolevulinate—Pruritus—Fludarabine—lymphatic system cancer	0.00545	0.00545	CcSEcCtD
Methyl aminolevulinate—Nausea—Teniposide—lymphatic system cancer	0.00521	0.00521	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Bleomycin—lymphatic system cancer	0.00508	0.00508	CcSEcCtD
Methyl aminolevulinate—Oedema—Carmustine—lymphatic system cancer	0.00493	0.00493	CcSEcCtD
Methyl aminolevulinate—Infection—Carmustine—lymphatic system cancer	0.0049	0.0049	CcSEcCtD
Methyl aminolevulinate—Rash—Fludarabine—lymphatic system cancer	0.00486	0.00486	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Fludarabine—lymphatic system cancer	0.00486	0.00486	CcSEcCtD
Methyl aminolevulinate—Pain—Bleomycin—lymphatic system cancer	0.00483	0.00483	CcSEcCtD
Methyl aminolevulinate—Headache—Fludarabine—lymphatic system cancer	0.00483	0.00483	CcSEcCtD
Methyl aminolevulinate—Discomfort—Mitoxantrone—lymphatic system cancer	0.00473	0.00473	CcSEcCtD
Methyl aminolevulinate—Oedema—Vincristine—lymphatic system cancer	0.00471	0.00471	CcSEcCtD
Methyl aminolevulinate—Infection—Vincristine—lymphatic system cancer	0.00468	0.00468	CcSEcCtD
Methyl aminolevulinate—Oedema—Mitoxantrone—lymphatic system cancer	0.00459	0.00459	CcSEcCtD
Methyl aminolevulinate—Nausea—Fludarabine—lymphatic system cancer	0.00458	0.00458	CcSEcCtD
Methyl aminolevulinate—Infection—Mitoxantrone—lymphatic system cancer	0.00456	0.00456	CcSEcCtD
Methyl aminolevulinate—Urticaria—Bleomycin—lymphatic system cancer	0.00449	0.00449	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Carmustine—lymphatic system cancer	0.00443	0.00443	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Vincristine—lymphatic system cancer	0.00423	0.00423	CcSEcCtD
Methyl aminolevulinate—Pain—Carmustine—lymphatic system cancer	0.00422	0.00422	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00417	0.00417	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00412	0.00412	CcSEcCtD
Methyl aminolevulinate—Fatigue—Vincristine—lymphatic system cancer	0.00406	0.00406	CcSEcCtD
Methyl aminolevulinate—Asthenia—Bleomycin—lymphatic system cancer	0.00406	0.00406	CcSEcCtD
Methyl aminolevulinate—Pain—Vincristine—lymphatic system cancer	0.00403	0.00403	CcSEcCtD
Methyl aminolevulinate—Pruritus—Bleomycin—lymphatic system cancer	0.004	0.004	CcSEcCtD
Methyl aminolevulinate—Fatigue—Mitoxantrone—lymphatic system cancer	0.00396	0.00396	CcSEcCtD
Methyl aminolevulinate—Pain—Mitoxantrone—lymphatic system cancer	0.00392	0.00392	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Methyl aminolevulinate—Urticaria—Mitoxantrone—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Carmustine—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Methyl aminolevulinate—Rash—Bleomycin—lymphatic system cancer	0.00356	0.00356	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Bleomycin—lymphatic system cancer	0.00356	0.00356	CcSEcCtD
Methyl aminolevulinate—Asthenia—Carmustine—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Vincristine—lymphatic system cancer	0.00347	0.00347	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Methyl aminolevulinate—Asthenia—Vincristine—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Methyl aminolevulinate—Nausea—Bleomycin—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Methyl aminolevulinate—Asthenia—Mitoxantrone—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Methyl aminolevulinate—Dizziness—Carmustine—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Methyl aminolevulinate—Dizziness—Vincristine—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Methyl aminolevulinate—Rash—Carmustine—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Carmustine—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Methyl aminolevulinate—Headache—Carmustine—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Methotrexate—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Methyl aminolevulinate—Rash—Vincristine—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Vincristine—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Methyl aminolevulinate—Headache—Vincristine—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Methyl aminolevulinate—Nausea—Carmustine—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Methyl aminolevulinate—Rash—Mitoxantrone—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Methyl aminolevulinate—Headache—Mitoxantrone—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Methyl aminolevulinate—Erythema—Methotrexate—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Methyl aminolevulinate—Nausea—Vincristine—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Methyl aminolevulinate—Nausea—Mitoxantrone—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Methyl aminolevulinate—Discomfort—Methotrexate—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Methyl aminolevulinate—Infection—Methotrexate—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Methotrexate—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Methyl aminolevulinate—Fatigue—Methotrexate—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Methyl aminolevulinate—Pain—Methotrexate—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Methyl aminolevulinate—Urticaria—Methotrexate—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Methyl aminolevulinate—Asthenia—Methotrexate—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Methyl aminolevulinate—Pruritus—Methotrexate—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Methyl aminolevulinate—Dizziness—Methotrexate—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Methyl aminolevulinate—Rash—Methotrexate—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Methotrexate—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Methyl aminolevulinate—Headache—Methotrexate—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Methyl aminolevulinate—Nausea—Methotrexate—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
